FDA Approval
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
Celgene Corporation
PR-M07-19-NI-068Jul 25, 2019
Collaboration
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
Jounce Therapeutics
PR-M07-19-NI-066Jul 25, 2019
M&A
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb
PR-M01-19-NI-017Jan 03, 2019
Clinical Trials
Celgene Announces Phase III ‘AUGMENT’ Study of REVLIMID® in Combination with Rituximab (R2)
Celgene Corporation
PR-M07-18-NI-085Jul 25, 2018
Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform
Skyhawk
PA4048Jun 28, 2018
CAR-T
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
bluebird bio, Inc.
PR-M03-18-NI-107Mar 30, 2018
Acquisition
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
Celgene Corporation
PR-M03-18-NI-034Mar 09, 2018
Drug Development
Celgene, Vividion Therapeutics Collaborate on Novel Protein Drugs
Guy Tiene
Nice Insight
PAO-M03-18-NI-005Mar 08, 2018
Acquistion
Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.
Celgene Corporation
PR-M02-18-NI-026Feb 08, 2018
Acqusition
Celgene Confirms $9 Billion Buyout of Juno Therapeutics
Guy Tiene
Nice Insight
PAO-M01-18-NI-039Jan 25, 2018
Acquisition
Impact Biomedicines Acquired By Celgene
Emilie Branch
Pharma's Almanac
PAO-M01-18-NI-027Jan 16, 2018
Innovation
Celgene’s First-Ever Oral Leukemia Treatment Gets FDA Nod
Nigel Walker
Nice Insight
PAO-M08-17-NI-012Aug 08, 2017
PD-1 Inhibitor
Celgene Corp. and BeiGene Enter Strategic Collaboration
Guy Tiene
Nice Insight
PAO-M07-17-NI-015Jul 13, 2017